ArticleBone reports2026

Comparison of KN012, a denosumab biosimilar, versus reference denosumab in Chinese postmenopausal women with osteoporosis: efficacy, safety, and population pharmacokinetics in a 12-month phase III study.

Xiufen Zhu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.